Vicora, Inc. — SEC Form D Filing

Vicora, Inc. filed an SEC Form D on September 18, 2026, reporting $2.30M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
September 18, 2026
Amount reported
$2.30M
Round stage
Seed
Industry
Medical Devices
Website
https://www.vicora.net/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients suffer from Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), which involves blood clots forming and potentially migrating to the lungs. Current methods can lead to issues like "Lollipopping" or "Corking" during PE treatment.

Solution

Vicora is developing the world's first catheter with integrated distal tip vibration to provide a simple and intuitive approach to clot removal. This device is designed to improve the efficiency of clot removal during thrombectomy procedures.

Why now

There's a continuous need for more effective and less invasive medical devices for treating thrombotic conditions like DVT and PE, driven by patient outcomes and healthcare efficiency. Advances in materials science and miniaturization allow for integrated features like vibrating tips in catheters.

Verdict

Investors backed this because the narrative presented a concrete technical solution to an acknowledged procedural problem in a lucrative market, not because it promised a disruptive shift in healthcare delivery. They were implicitly betting on the team's ability to execute on a highly specific engineering challenge and navigate medical device regulatory pathways. The limited upside stemmed from the solution's niche application within a larger treatment paradigm, rather than a broad redefinition of care.

Source: SEC EDGAR Form D filing